# VEGFA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- VEGFA is a critical regulator of angiogenesis, vasculogenesis, and lymphangiogenesis, encoded by a gene on chromosome 6p21.1 that produces multiple isoforms via alternative splicing, influencing bioavailability and receptor binding.
- The primary signaling pathway involves VEGFA binding to receptor tyrosine kinases VEGFR1 and VEGFR2, with co-receptor engagement by Neuropilins, mediating downstream effects on endothelial cell proliferation, survival, migration, and permeability.
- Dysregulation of VEGFA, including overexpression and altered isoform ratios, is central to tumor angiogenesis, ischemic diseases, and inflammatory conditions, making it a key therapeutic target in oncology and ophthalmology.
- Clinical interventions include monoclonal antibodies (e.g., bevacizumab, ranibizumab) and small-molecule tyrosine kinase inhibitors (e.g., sunitinib, sorafenib) that target VEGFA or its receptors, with specific pharmacogenomic considerations and resistance mechanisms influencing treatment outcomes.
- Germline and somatic genetic variations, including promoter polymorphisms and gene amplifications, are associated with differential VEGFA expression and disease susceptibility, impacting conditions such as hereditary hemorrhagic telangiectasia, preeclampsia, and various cancers.
- Viral and bacterial pathogens can exploit VEGFA signaling pathways to promote their own proliferation and dissemination, often by inducing VEGFA transcription or modulating its bioavailability within the host.

---

## Executive Summary & Key Metadata

Vascular Endothelial Growth Factor A (VEGFA) is the master regulator of angiogenesis, vasculogenesis, and lymphangiogenesis. Encoded by a single gene on chromosome 6p21.1, VEGFA produces multiple isoforms through alternative splicing, each with distinct bioavailability and receptor-binding properties. The mature protein functions as a homodimeric, disulfide-linked glycoprotein that signals through receptor tyrosine kinases VEGFR1 (FLT1) and VEGFR2 (KDR), with co-receptor engagement from Neuropilins (NRP1/NRP2). Beyond its canonical role in developmental vascular patterning, VEGFA is a central effector in tumor angiogenesis, ischemic revascularization, and inflammatory neovascularization. Its clinical relevance is underscored by the success of anti-VEGFA biologics (e.g., bevacizumab, ranibizumab, aflibercept) and small-molecule tyrosine kinase inhibitors (e.g., sunitinib, sorafenib) in oncology and ophthalmology.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | VEGFA |
| UniProt Accession | P15692 |
| Representative PDB ID | 1VPF (VEGF-A homodimer with VEGFR1 domain 2) |
| Chromosomal Locus | 6p21.1 (GRCh38: chr6:43,770,184-43,794,562, minus strand) |
| Primary Molecular Function | Growth factor activity; VEGFR1/VEGFR2 receptor binding; heparin binding; neuropilin binding |
| Disease & Pathology Associations | Tumor angiogenesis, age-related macular degeneration (AMD), diabetic retinopathy, preeclampsia, rheumatoid arthritis, hereditary hemorrhagic telangiectasia (modifier) |
| Isoforms | VEGF121, VEGF165, VEGF189, VEGF206 (major); plus VEGF145, VEGF183, VEGF162, VEGF165b (inhibitory) |
| Protein Length (canonical) | 232 amino acids (preproprotein); 165 aa mature secreted form (VEGF165) |
| Post-translational Modifications | N-glycosylation (Asn75), disulfide bonds, proteolytic processing |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Architecture

The human *VEGFA* gene spans approximately 24.4 kilobases (kb) on the minus strand of chromosome 6 at cytogenetic band 6p21.1 (GRCh38 coordinates: chr6:43,770,184–43,794,562). The gene comprises 8 exons interspersed with 7 introns, a structure highly conserved across mammals. The genomic organization is notable for its complex 5' untranslated region (UTR) and alternative promoter usage, which permits tissue-specific and hypoxia-inducible expression.

The core promoter region lacks a canonical TATA box but contains multiple GC-rich Sp1 binding sites, an AP-1/AP-2 consensus sequence, and a hypoxia-responsive element (HRE) located approximately 1 kb upstream of the transcription start site (TSS). The HRE contains the consensus sequence 5'-RCGTG-3' that binds Hypoxia-Inducible Factor 1 alpha (HIF-1α) in complex with HIF-1β (ARNT). Under normoxic conditions, HIF-1α is hydroxylated on proline residues 402 and 564 by prolyl hydroxylase domain enzymes (PHD1-3), targeting it for von Hippel-Lindau (VHL)-mediated ubiquitination and proteasomal degradation. Hypoxia or VHL loss stabilizes HIF-1α, driving robust VEGFA transcription.

### 1.2 Enhancer Elements and Epigenetic Regulation

Three evolutionary conserved enhancer regions have been characterized: (i) a distal enhancer at -2.5 kb containing a hypoxia-responsive enhancer sequence (HRES) that synergizes with the proximal HRE; (ii) an intragenic enhancer within intron 1 that binds ETS family transcription factors (ETS1, ETS2) and GATA2; and (iii) a 3' enhancer element that responds to TGF-β signaling via SMAD3/SMAD4 binding. Chromatin immunoprecipitation (ChIP-seq) studies in endothelial cells reveal that VEGFA locus is marked by H3K27ac and H3K4me1 at these enhancers, with dynamic remodeling upon angiogenic stimulation.

Single-nucleotide polymorphisms (SNPs) in the VEGFA promoter and 5' UTR, notably rs699947 (-2578C/A), rs1570360 (-1154G/A), and rs2010963 (-634G/C), have been associated with differential VEGFA expression levels and disease susceptibility. The -2578C/A polymorphism resides within a potential HIF-1α binding site, and the A allele correlates with lower circulating VEGF levels in some populations.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of exons 6, 7, and 8 generates multiple VEGFA isoforms with distinct biochemical properties. The primary mechanism involves differential inclusion of the heparin-binding domains encoded by exons 6 and 7, and alternative 3' splice site selection in exon 8 that produces either pro-angiogenic (VEGFxxx) or anti-angiogenic (VEGFxxxb) isoforms.

| **Isoform** | **Amino Acids (mature)** | **Exon Composition** | **Heparin Binding** | **Bioavailability** | **Function** |
|---|---|---|---|---|---|
| VEGF121 | 121 | Exons 1-5, 8a | None | Freely diffusible | Pro-angiogenic |
| VEGF145 | 145 | Exons 1-5, 6a, 8a | Moderate | Matrix-associated | Pro-angiogenic |
| VEGF165 | 165 | Exons 1-5, 7a, 8a | High | Partially matrix-bound | Predominant pro-angiogenic isoform |
| VEGF183 | 183 | Exons 1-5, 6a, 7a, 8a | High | Matrix-bound | Pro-angiogenic |
| VEGF189 | 189 | Exons 1-5, 6a, 6b, 7a, 8a | Very high | Sequestered in ECM | Pro-angiogenic (released by proteases) |
| VEGF206 | 206 | Exons 1-5, 6a, 6b, 7a, 7b, 8a | Very high | Sequestered in ECM | Pro-angiogenic |
| VEGF165b | 165 | Exons 1-5, 7a, 8b | High | Diffusible | Anti-angiogenic (competitive inhibitor) |

The anti-angiogenic isoforms (VEGFxxxb family) arise from use of a distal 3' splice site in exon 8, shifting the reading frame to encode a C-terminal sequence (SLTRKD) instead of the pro-angiogenic CDKPRR motif. VEGF165b binds VEGFR2 with similar affinity but fails to induce receptor autophosphorylation at Tyr1175, thereby acting as a partial agonist/antagonist. Downregulation of VEGFxxxb splicing is observed in several malignancies, contributing to an angiogenic switch.

### 1.4 Transcriptional Regulation

Beyond HIF-1α, VEGFA transcription is regulated by numerous transcription factors including:
- **SP1/SP3**: Constitutive and inducible expression via GC-boxes
- **AP-1 (FOS/JUN)**: Mediates response to phorbol esters, growth factors
- **STAT3**: Activated by IL-6 and oncogenic signaling
- **p53**: Represses VEGFA transcription under genotoxic stress
- **MYC**: Directly binds the VEGFA promoter in cancer cells
- **NF-κB**: Induced by inflammatory cytokines (TNF-α, IL-1β)

Post-transcriptional regulation is equally critical. The 3' UTR of VEGFA mRNA contains multiple AU-rich elements (AREs) that mediate rapid degradation via the RNA-binding proteins tristetraprolin (TTP/ZFP36) and AUF1. Hypoxia stabilizes VEGFA mRNA through binding of HuR (ELAVL1) to the AREs, extending mRNA half-life from ~30 minutes to several hours. Additionally, microRNAs including miR-16, miR-29b, miR-126, and miR-200b negatively regulate VEGFA expression by targeting the 3' UTR.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Processing

The VEGFA preproprotein is 232 amino acids in length. Signal peptide cleavage (residues 1-26) occurs during co-translational translocation into the endoplasmic reticulum (ER), yielding a 206-residue proprotein. Proteolytic removal of the C-terminal heparin-binding domain by plasmin and matrix metalloproteinases (MMP-3, MMP-9) generates the mature secreted forms. The canonical VEGF165 isoform (165 residues) is the most abundant and biologically active.

### 2.2 Secondary and Tertiary Structure

The mature VEGFA monomer adopts a cystine-knot growth factor fold, structurally homologous to platelet-derived growth factor (PDGF) and placenta growth factor (PlGF). The monomer comprises:
- **N-terminal α-helix** (residues 11-25 in mature numbering): Involved in receptor dimerization interface
- **Two β-sheet pairs** (β1-β2 and β3-β4): Form the central antiparallel β-sheet core
- **Cystine-knot motif**: Formed by three conserved disulfide bonds (Cys26-Cys68, Cys57-Cys104, Cys61-Cys102 in mature VEGF165 numbering) that stabilize the fold
- **Receptor-binding loops**: Loops L1, L2, and L3 (between β-strands) constitute the primary VEGFR binding surface

The functional unit is an antiparallel homodimer, with the two monomers oriented such that their receptor-binding surfaces are positioned at opposite poles. The dimer interface buries approximately 2,400 Ų of solvent-accessible surface area and is stabilized by both hydrophobic interactions and two symmetrical disulfide bonds (Cys51-Cys51' and Cys60-Cys60' in the mature protein).

### 2.3 Receptor-Binding Epitopes

Mutagenesis studies have mapped the VEGFR2-binding site to a discontinuous epitope comprising residues from the L2 loop (Arg82, Lys84, His86), the L3 loop (Asp63, Glu64, Glu67), and the N-terminal helix (Phe17, Tyr21, Gln22, Ile43, Ile46). The VEGFR1-binding site overlaps partially but is distinguished by higher affinity (Kd ≈ 2-10 pM for VEGFR1 vs. 75-760 pM for VEGFR2). Key residues for VEGFR1 binding include Asp63, Glu64, and Glu67, while VEGFR2 specificity is conferred by Ile43, Ile46, and Gln79.

Heparin-binding domains (encoded by exons 6 and 7) form a highly basic patch (pI > 9.5) on the dimer surface, enabling interaction with heparan sulfate proteoglycans (HSPGs) on the cell surface and extracellular matrix. This interaction concentrates VEGFA at the cell surface and presents it to VEGFR2 in an optimal orientation, enhancing receptor activation.

### 2.4 Post-Translational Modifications

- **N-glycosylation**: Asn75 in the mature protein is N-glycosylated; this modification is required for efficient secretion but not for receptor binding
- **Disulfide bonds**: Six intramolecular (three per monomer) and two intermolecular disulfides stabilize the dimer
- **Proteolytic processing**: Cleavage by plasmin at Arg110-Ala111 generates VEGF110, a truncated but fully active form lacking heparin-binding domains

### 2.5 Structural Insights from Crystallography

The high-resolution crystal structure of VEGF-A in complex with domain 2 of VEGFR1 (PDB: 1FLT) and domain 2 of VEGFR2 (PDB: 3V2A) revealed that the receptor-binding interface is dominated by hydrophobic interactions, with a central phenylalanine (Phe17) of VEGFA inserting into a hydrophobic pocket on the receptor. The structure of the VEGFA-VEGFR2 complex (PDB: 3V2A) shows that VEGFR2 domain 2 (D2) binds at the VEGFA dimer interface, while domain 3 (D3) makes additional contacts that confer ligand specificity. More recent cryo-EM structures of the full-length VEGFR2 dimer in complex with VEGFA (PDB: 6V6V) demonstrate that ligand binding induces a conformational rearrangement that brings the intracellular kinase domains into proximity, enabling trans-autophosphorylation.

> **Interactive 3D Protein Visualizer: Load VEGFA (PDB: 1VPF)**
> [Interactive 3D Protein Visualizer: Load VEGFA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P15692)
>
> This visualizer renders the VEGFA homodimer (PDB: 1VPF) with color-coded domains: the receptor-binding loops (red), the cystine-knot core (blue), and the heparin-binding domain (green). Users can rotate the structure, toggle between cartoon and surface representations, and measure interatomic distances at the dimer interface.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 VEGFR2-Mediated Signaling

VEGFA exerts its primary angiogenic effects through VEGFR2 (KDR/Flk-1), a class III receptor tyrosine kinase. Ligand-induced dimerization of VEGFR2 triggers trans-autophosphorylation at multiple cytoplasmic tyrosine residues, creating docking sites for downstream signaling molecules:

| **Phosphotyrosine** | **Binding Partner** | **Signaling Pathway** |
|---|---|---|
| Tyr951 | TSAd (SH2D2A) | Cell migration, actin reorganization |
| Tyr1054/Tyr1059 | Kinase activation loop | Catalytic activity |
| Tyr1175 | PLCγ, SHB, SCK | Proliferation, permeability (via PKC-ERK) |
| Tyr1214 | NCK | Cell migration via PAK2/c-Jun |

The Tyr1175 residue is the dominant signaling node. Phosphorylation at this site recruits phospholipase Cγ (PLCγ), which hydrolyzes PIP2 to generate IP3 and DAG. IP3 triggers calcium release from ER stores, activating endothelial nitric oxide synthase (eNOS) and promoting vascular permeability. DAG activates protein kinase C (PKC), particularly PKCβ, which initiates the RAF-MEK-ERK cascade, driving endothelial cell proliferation. The Tyr1175-SHC-GRB2-GAB1 axis activates PI3K, generating PIP3 and recruiting AKT, which promotes endothelial survival via BAD phosphorylation and mTOR activation.

### 3.2 VEGFR1 Signaling and Decoy Function

VEGFR1 (FLT1) binds VEGFA with ~10-fold higher affinity than VEGFR2 but exhibits weak tyrosine kinase activity. In endothelial cells, VEGFR1 functions primarily as a "decoy" receptor, sequestering VEGFA and modulating its availability to VEGFR2. However, in monocytes, macrophages, and certain tumor cells, VEGFR1 signaling through Tyr1213 activates PI3K-AKT and p38 MAPK pathways, promoting cell migration and survival. The soluble form of VEGFR1 (sFLT1), generated by alternative splicing, acts as a potent endogenous VEGFA antagonist and is implicated in preeclampsia pathogenesis.

### 3.3 Co-Receptor Function: Neuropilins and HSPGs

Neuropilin-1 (NRP1) binds VEGF165 (but not VEGF121) via the exon 7-encoded domain, forming a ternary complex with VEGFR2. NRP1 enhances VEGFR2 signaling by: (i) increasing local ligand concentration; (ii) stabilizing the VEGFR2 dimer; and (iii) promoting VEGFR2 internalization and recycling. NRP1 also mediates VEGFA-independent signaling through its cytoplasmic PDZ-binding motif, which interacts with synectin (GIPC1) to regulate arterial specification.

Heparan sulfate proteoglycans (HSPGs) on the cell surface and ECM bind VEGFA via its heparin-binding domain, creating a concentration gradient that guides endothelial sprouting. The sulfation pattern of heparan sulfate determines VEGFA binding affinity, with 2-O- and 6-O-sulfation being critical for high-affinity interaction.

### 3.4 Downstream Effectors and Biological Outcomes

The integrated VEGFA signaling network orchestrates multiple endothelial cell behaviors:

- **Proliferation**: ERK1/2 activation induces cyclin D1 and c-Myc expression, driving G1/S transition
- **Survival**: PI3K-AKT signaling inhibits pro-apoptotic proteins (BAD, FOXO, caspase-9) and upregulates anti-apoptotic BCL-2 and survivin
- **Migration**: Activation of focal adhesion kinase (FAK), paxillin, and small GTPases (Rac1, Cdc42) promotes lamellipodia formation and directional migration
- **Permeability**: Src-mediated phosphorylation of VE-cadherin and β-catenin disrupts adherens junctions; eNOS-derived NO induces vasodilation
- **Tube formation**: Coordinated activation of Notch/DLL4 signaling establishes tip/stalk cell specification during sprouting angiogenesis

### 3.5 Feedback Regulation

VEGFA signaling is tightly regulated by multiple negative feedback loops:

1. **Soluble VEGFR1 (sFLT1)**: Hypoxia-induced alternative splicing generates sFLT1, which sequesters VEGFA in the extracellular space
2. **VEGFR2 internalization**: Ligand-bound VEGFR2 is internalized via clathrin-mediated endocytosis and either recycled or degraded in lysosomes
3. **Protein tyrosine phosphatases**: SHP-1, SHP-2, and DEP-1 dephosphorylate VEGFR2, attenuating signaling
4. **Sprouty proteins**: SPRY2 and SPRY4 inhibit the RAF-MEK-ERK cascade downstream of VEGFR2
5. **miRNA regulation**: miR-126 targets SPRED1 and PI3KR2, indirectly enhancing VEGFA signaling; conversely, miR-16 and miR-29b directly suppress VEGFA mRNA

### 3.6 Protein-Protein Interaction Network

STRING analysis (confidence score >0.9) identifies the core VEGFA interactome comprising:

- **Receptors**: FLT1 (VEGFR1), KDR (VEGFR2), NRP1, NRP2
- **Signaling adaptors**: SHC1, GRB2, PLCG1, PIK3R1, SRC, SH2D2A
- **Transcriptional regulators**: HIF1A, EPAS1 (HIF2A), SP1, STAT3
- **Extracellular modulators**: HSPG2, SDC1, SDC2, FN1
- **Proteases**: MMP2, MMP9, PLG (plasminogen), ADAMTS1

BioGRID lists over 120 physical interactions for VEGFA, including direct binding to VEGFR1 (Kd ≈ 10 pM), VEGFR2 (Kd ≈ 75 pM), NRP1 (Kd ≈ 3 nM), and heparan sulfate.

```mermaid
sequenceDiagram
    participant EC as "Endothelial Cell"
    participant V as "VEGFA Dimer"
    participant R2 as "VEGFR2"
    participant PLC as "PLCγ"
    participant PKC as "PKCβ"
    participant ERK as "RAF-MEK-ERK"
    participant PI3K as "PI3K-AKT"
    participant N as "Nucleus"
    V->>R2: Ligand-induced dimerization
    R2->>R2: Trans-autophosphorylation (Y1175)
    R2->>PLC: Recruitment via SH2 domain
    PLC->>PLC: PIP2 hydrolysis → IP3 + DAG
    PLC->>PKC: DAG activates PKCβ
    PKC->>ERK: RAF activation → MEK → ERK
    ERK->>N: Phosphorylates transcription factors (ELK1, c-FOS)
    R2->>PI3K: SHC-GRB2-GAB1 recruitment
    PI3K->>PI3K: PIP3 generation
    PI3K->>N: AKT activation → survival genes
    N->>N: Proliferation, migration, survival gene expression
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Mendelian Disorders

Unlike classical tumor suppressor genes or oncogenes, germline mutations in VEGFA itself are rare and typically not disease-causing in isolation. However, VEGFA acts as a critical modifier gene in several vascular disorders:

- **Hereditary Hemorrhagic Telangiectasia (HHT)**: Mutations in ENG (endoglin) or ACVRL1 (ALK1) cause HHT; VEGFA polymorphisms modulate disease expressivity, particularly pulmonary arteriovenous malformation risk
- **Preeclampsia**: Elevated sFLT1 and reduced free VEGFA levels are pathognomonic; VEGFA promoter polymorphisms (rs2010963) associate with preeclampsia susceptibility in meta-analyses
- **Diabetic Retinopathy**: The -634G/C polymorphism (rs2010963) is associated with increased VEGFA expression and proliferative diabetic retinopathy risk in Asian populations

### 4.2 Somatic Mutations in Cancer

Somatic VEGFA mutations are uncommon in most cancers, but gene amplification and overexpression are frequent. The Cancer Genome Atlas (TCGA) data reveal:

- **Amplification**: VEGFA copy-number gains occur in ~10-15% of glioblastomas, ~8% of ovarian cancers, and ~5% of breast cancers
- **Mutations**: Recurrent missense mutations are rare (<2% across cancer types); most are passenger mutations without functional consequence
- **Expression dysregulation**: VEGFA mRNA is overexpressed in >50% of solid tumors, driven by HIF-1α stabilization (VHL loss in renal cell carcinoma), MYC amplification, or RAS/RAF pathway activation

### 4.3 Functional Polymorphisms and Disease Association

| **Variant** | **Location** | **Functional Consequence** | **Disease Association** |
|---|---|---|---|
| rs699947 (-2578C/A) | Promoter | Reduced promoter activity (A allele) | Lower AMD risk; reduced breast cancer angiogenesis |
| rs1570360 (-1154G/A) | Promoter | Reduced transcription factor binding | Associated with recurrent pregnancy loss |
| rs2010963 (-634G/C) | 5' UTR | Altered translation efficiency | Increased diabetic retinopathy, AMD risk |
| rs3025039 (+936C/T) | 3' UTR | Reduced mRNA stability (T allele) | Lower circulating VEGF; protective in some cancers |
| rs833061 (-460T/C) | Promoter | Altered SP1 binding | Associated with rheumatoid arthritis severity |

### 4.4 ClinVar Pathogenic Variants

ClinVar currently lists 38 variants in VEGFA, of which 12 are classified as pathogenic or likely pathogenic. These include:

- **c.358C>T (p.Arg120Cys)**: Disrupts a conserved disulfide bond (Cys120-Cys158), impairing dimerization; associated with isolated lymphedema in one family
- **c.419G>A (p.Cys140Tyr)**: Abolishes a structural cysteine; predicted to destabilize the cystine-knot fold
- **c.500G>A (p.Arg167His)**: Located in the heparin-binding domain; reduces ECM sequestration and alters bioavailability

Most ClinVar entries are variants of uncertain significance (VUS) in the promoter or intronic regions, reflecting the difficulty of interpreting non-coding variants in a gene with complex regulatory architecture.

### 4.5 Differential Diagnosis and Clinical Testing

VEGFA testing is not routine in clinical genetics, but measurement of circulating VEGFA levels has diagnostic utility:

- **Elevated VEGFA**: Active proliferative retinopathy, preeclampsia (with elevated sFLT1), certain malignancies (renal cell carcinoma, hepatocellular carcinoma)
- **Reduced VEGFA**: Some cases of preeclampsia (free VEGFA), cardiovascular disease risk

In oncology, tumor VEGFA expression by immunohistochemistry or mRNA in situ hybridization is used as a predictive biomarker for anti-angiogenic therapy response, though results have been inconsistent across trials.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of VEGFA

Several viruses have evolved mechanisms to manipulate VEGFA signaling for their benefit:

- **Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8)**: The viral G protein-coupled receptor (vGPCR) constitutively activates HIF-1α, driving VEGFA transcription. KSHV also encodes a viral IL-6 that induces VEGFA via STAT3. This paracrine VEGFA secretion is essential for the spindle cell proliferation and angiogenesis characteristic of Kaposi's sarcoma.
- **Epstein-Barr Virus (EBV)**: The latent membrane protein 1 (LMP1) upregulates VEGFA through NF-κB and AP-1 signaling in nasopharyngeal carcinoma, promoting tumor angiogenesis.
- **Hepatitis B and C Viruses**: HBV X protein (HBx) stabilizes HIF-1α and activates VEGFA transcription; HCV core protein induces VEGFA via the Wnt/β-catenin pathway. Both contribute to hepatocellular carcinoma hypervascularity.
- **Human Papillomavirus (HPV)**: HPV16 E6/E7 oncoproteins upregulate VEGFA through HIF-1α stabilization (E6) and degradation of p53 (E7), promoting cervical cancer angiogenesis.
- **SARS-CoV-2**: Severe COVID-19 is associated with elevated VEGFA levels, contributing to endothelial dysfunction and microvascular thrombosis. The viral spike protein can directly activate VEGFR2 signaling in endothelial cells.

### 5.2 Bacterial Interactions

- **Mycobacterium tuberculosis**: Infection induces VEGFA in granulomas, promoting angiogenesis that facilitates bacterial dissemination. M. tuberculosis ESAT-6 protein upregulates VEGFA via TLR2-MAPK signaling.
- **Helicobacter pylori**: CagA-positive strains induce VEGFA in gastric epithelial cells via NF-κB, contributing to gastric cancer angiogenesis.
- **Porphyromonas gingivalis**: Gingipain proteases degrade VEGFA, impairing periodontal angiogenesis and wound healing.

### 5.3 Parasitic Interactions

- **Plasmodium falciparum**: Cerebral malaria is associated with elevated VEGFA, which disrupts the blood-brain barrier. Parasite-derived histidine-rich protein II (HRPII) binds VEGFA and modulates its bioavailability.
- **Toxoplasma gondii**: Infection upregulates VEGFA in the retina, contributing to ocular toxoplasmosis-associated neovascularization.

### 5.4 Immune Evasion Mechanisms

Tumors exploit VEGFA to evade immune surveillance through multiple mechanisms:

1. **Inhibition of dendritic cell maturation**: VEGFA suppresses NF-κB activation in DCs, reducing antigen presentation
2. **Expansion of regulatory T cells (Tregs)**: VEGFA promotes Treg proliferation via VEGFR2 signaling
3. **Suppression of cytotoxic T lymphocyte (CTL) function**: VEGFA downregulates ICAM-1 on endothelial cells, reducing CTL extravasation
4. **Myeloid-derived suppressor cell (MDSC) recruitment**: VEGFA attracts MDSCs to the tumor microenvironment, which suppress T-cell responses

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Anti-VEGFA Therapies

| **Drug** | **Class** | **Mechanism** | **Indications** | **Route** |
|---|---|---|---|---|
| Bevacizumab (Avastin) | Humanized monoclonal antibody | Binds all VEGFA isoforms | Metastatic colorectal, NSCLC, renal cell, glioblastoma, cervical cancer | IV |
| Ranibizumab (Lucentis) | Humanized Fab fragment | Binds VEGFA with high affinity | Neovascular AMD, diabetic macular edema, retinal vein occlusion | Intravitreal |
| Aflibercept (Eylea) | VEGFR1/2-Fc fusion protein | Traps VEGFA and PlGF | Neovascular AMD, diabetic macular edema, colorectal cancer (Zaltrap) | Intravitreal/IV |
| Conbercept (Lumitin) | VEGFR1/2-Fc fusion protein | Traps VEGFA, VEGFB, PlGF | Neovascular AMD (approved in China) | Intravitreal |
| Brolucizumab (Beovu) | Single-chain antibody fragment | Binds VEGFA | Neovascular AMD | Intravitreal |
| Pegaptanib (Macugen) | Pegylated aptamer | Binds VEGF165 specifically | Neovascular AMD | Intravitreal |

### 6.2 Small-Molecule Tyrosine Kinase Inhibitors (TKIs)

Multi-target TKIs that inhibit VEGFR2 (and often VEGFR1, PDGFR, FGFR, c-KIT) are approved for multiple solid tumors:

- **Sunitinib (Sutent)**: Renal cell carcinoma, GIST, pancreatic NET
- **Sorafenib (Nexavar)**: Hepatocellular carcinoma, renal cell carcinoma, thyroid cancer
- **Pazopanib (Votrient)**: Renal cell carcinoma, soft tissue sarcoma
- **Axitinib (Inlyta)**: Renal cell carcinoma
- **Lenvatinib (Lenvima)**: Thyroid cancer, hepatocellular carcinoma, renal cell carcinoma
- **Vandetanib (Caprelsa)**: Medullary thyroid cancer
- **Cabozantinib (Cabometyx)**: Renal cell carcinoma, hepatocellular carcinoma

### 6.3 Investigational Agents and Emerging Strategies

- **Bispecific antibodies**: Faricimab (Vabysmo) targets both VEGFA and Ang-2; approved for neovascular AMD and diabetic macular edema
- **VEGF-A/PDGF-B bispecific**: Investigational for AMD
- **siRNA therapeutics**: Bevacizumab-siRNA conjugates for sustained ocular delivery
- **Gene therapy**: AAV-mediated expression of sFLT1 (RGX-314) for wet AMD; phase III trials ongoing
- **VEGFxxxb mimetics**: Peptides based on the anti-angiogenic VEGF165b C-terminus are in preclinical development
- **VEGFR2-targeted CAR-T cells**: Investigational for solid tumors

### 6.4 Pharmacogenomic Considerations

- **VEGFA polymorphisms and response**: The rs2010963 (-634G/C) variant has been associated with differential response to bevacizumab in metastatic colorectal cancer, though results are inconsistent across studies
- **Hypertension as a biomarker**: TKI-induced hypertension correlates with improved outcomes, reflecting on-target VEGFR2 inhibition
- **Proteinuria**: A common dose-limiting toxicity of anti-VEGFA therapy, resulting from disruption of glomerular endothelial homeostasis

### 6.5 Resistance Mechanisms

Resistance to anti-VEGFA therapy arises through:

1. **Upregulation of alternative angiogenic factors**: FGF2, PDGF-B, Angiopoietin-2, PlGF
2. **Vessel co-option**: Tumors grow along pre-existing vessels without neoangiogenesis
3. **Increased invasiveness**: Anti-angiogenic therapy can promote epithelial-mesenchymal transition and metastasis
4. **Pericyte coverage**: Recruitment of pericytes protects endothelial cells from VEGFA withdrawal
5. **Myeloid cell infiltration**: Tumor-associated macrophages secrete alternative pro-angiogenic factors

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 7422 | https://www.ncbi.nlm.nih.gov/gene/7422 |
| Ensembl | ENSG00000112715 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112715 |
| UniProt | P15692 | https://www.uniprot.org/uniprotkb/P15692 |
| RCSB PDB | 1VPF, 1FLT, 3V2A, 6V6V | https://www.rcsb.org/search?q=accession%3A1VPF |
| ClinVar | Gene: VEGFA | https://www.ncbi.nlm.nih.gov/clinvar/?term=VEGFA%5Bgene%5D |
| COSMIC | Gene: VEGFA | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=VEGFA |
| STRING | 9606.ENSP00000380261 | https://string-db.org/network/9606.ENSP00000380261 |
| BioGRID | 113639 | https://thebiogrid.org/113639 |
| Gene Ontology | GO:0008083 (growth factor activity), GO:0005178 (integrin binding), GO:0048010 (VEGFR signaling) | https://www.ebi.ac.uk/QuickGO/ |
| Reactome | R-HSA-194138 (VEGFA-VEGFR2 pathway) | https://reactome.org/content/detail/R-HSA-194138 |
| KEGG | hsa:7422 | https://www.genome.jp/dbget-bin/www_bget?hsa:7422 |
| GWAS Catalog | VEGFA | https://www.ebi.ac.uk/gwas/genes/VEGFA |
| Human Protein Atlas | ENSG00000112715 | https://www.proteinatlas.org/ENSG00000112715-VEGFA |
| PharmGKB | PA37312 | https://www.pharmgkb.org/gene/PA37312 |

### Gene Ontology Annotations

| **Category** | **GO Term** | **Annotation** |
|---|---|---|
| Molecular Function | GO:0008083 | Growth factor activity |
| Molecular Function | GO:0005178 | Integrin binding |
| Molecular Function | GO:0008201 | Heparin binding |
| Molecular Function | GO:0005515 | Protein binding |
| Biological Process | GO:0001525 | Angiogenesis |
| Biological Process | GO:0048010 | Vascular endothelial growth factor receptor signaling pathway |
| Biological Process | GO:0001938 | Positive regulation of endothelial cell proliferation |
| Biological Process | GO:0043542 | Endothelial cell migration |
| Biological Process | GO:0001666 | Response to hypoxia |
| Cellular Component | GO:0005615 | Extracellular space |
| Cellular Component | GO:0005576 | Extracellular region |
| Cellular Component | GO:0031012 | Extracellular matrix |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nature Medicine*. 2003;9(6):669-676. https://www.nature.com/articles/nm0603-669

2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science*. 1989;246(4935):1306-1309. https://www.science.org/doi/10.1126/science.2479986

3. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. *Journal of Biological Chemistry*. 1991;266(18):11947-11954. https://www.jbc.org/article/S0021-9258(18)99049-6/fulltext

4. Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. *Cell*. 1997;91(5):695-704. https://www.cell.com/cell/fulltext/S0092-8674(00)80456-0

5. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, de Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. *Proceedings of the National Academy of Sciences*. 1997;94(14):7192-7197. https://www.pnas.org/doi/10.1073/pnas.94.14.7192

6. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, and signalling. *Cellular and Molecular Life